Previous
Previous

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

Next
Next

Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise